ERBB2 and breast cancer: These patients were treated for 152 ER-positive, HER2-negative, node-negative early breast cancers. Of the 133 patients, the proportion of patients presenting symptomatically compared to those with breast cancer detected through national screening was not significantly different (51.1% and 48.9%, respectively).